Valuation: Orion Oyj

Market Cap 11.4B 13.11B 10.61B 9.74B 18.39B 1,251B 18.67B 125B 49.07B 623B 49.23B 48.15B 2,089B P/E 2026 *
20.1x
P/E 2027 * 17.3x
Enterprise Value 11.29B 12.99B 10.51B 9.65B 18.22B 1,240B 18.5B 124B 48.61B 617B 48.77B 47.7B 2,069B EV / Sales 2026 *
5.39x
EV / Sales 2027 * 4.68x
Free-Float
90.5%
Yield 2026 *
2.39%
Yield 2027 * 2.67%
1 day+4.81%
6 months+1.78%
Current year+1.78%
Current year 78.95
Extreme 78.95
82.75
1 year 78.95
Extreme 78.95
82.75
3 years 37
Extreme 37
82.75
5 years 37
Extreme 37
82.75
10 years 27.35
Extreme 27.35
82.75
Manager TitleAgeSince
Chief Executive Officer 59 31/10/2022
Director of Finance/CFO 50 30/04/2024
Chief Operating Officer 46 31/12/2021
Director TitleAgeSince
Director/Board Member 63 21/03/2017
Director/Board Member 65 21/03/2017
Director/Board Member 66 05/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
+4.81%-.--% - - 13.12B
-0.83%-4.40%+54.50%+151.54% 1,030B
+0.95%-2.13%+56.48%+53.88% 617B
-2.18%-3.09%+32.97%+68.03% 455B
+0.06%-0.42%+37.53%+30.67% 350B
-0.14%-0.24%+34.41%+39.01% 299B
-0.69%-0.30%+11.55%+12.93% 265B
-7.37%-4.40%-2.54%-43.87% 225B
-0.31%+2.48%+30.58%+64.57% 209B
-0.43%+0.70%+15.97%+71.03% 163B
Average -0.56%+4.83%+30.16%+49.75% 401.41B
Weighted average by Cap. -0.83%+4.87%+38.99%+72.31%

Financials

2026 *2027 *
Net sales 2.09B 2.41B 1.95B 1.79B 3.38B 230B 3.43B 22.98B 9.02B 114B 9.05B 8.85B 384B 2.35B 2.71B 2.19B 2.01B 3.8B 258B 3.86B 25.83B 10.14B 129B 10.17B 9.95B 432B
Net income 566M 651M 527M 483M 913M 62.13B 927M 6.21B 2.44B 30.93B 2.44B 2.39B 104B 651M 749M 606M 556M 1.05B 71.49B 1.07B 7.14B 2.8B 35.59B 2.81B 2.75B 119B
Net Debt -107M -123M -99.83M -91.65M -173M -11.78B -176M -1.18B -462M -5.86B -463M -453M -19.66B -369M -424M -343M -315M -595M -40.48B -604M -4.04B -1.59B -20.15B -1.59B -1.56B -67.58B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,000
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
80.95EUR
Average target price
76.50EUR
Spread / Average Target
-5.50%

Quarterly revenue - Rate of surprise